NFKB1 and metabolic dysfunction-associated steatohepatitis: Zeng et al. [36] recently reported that DMY treatment increased hepatic SIRT1 expression and subsequently repressed the NF-κB signal pathway in nonalcoholic steatohepatitis (NASH) mice.